Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) https://validator.w3.org/feed/docs/rss2.html White Paper Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) Member Contents Our Team Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy Basic Cancer Immunology for Clinicians A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML TTCI at a glance CAR T-cell Immunometabolism: Insights from Patients Chiang Mai University Team Mahidol University Team TTCI to Participate in WIC-APAC 2026 Pediatric Neuro-Oncology Consortium – Chulalongkorn University Research Forum Personalized Cancer Vaccines – A New Frontier in Thailand’s Fight Against Cancer Scientific Meeting: Medical Applications of Gene Editing and Synthetic Biology Technologies CAR T-cell therapy for paediatric solid tumours: clinical trial development and preclinical modelling NRCT Hosts Seminar on “Thai Cancer Immunotherapy: Collaboration, Regulation, and the Future of Treatment” at MHESI Fair 2025 Thai Immunology Annual Meeting 2026 IPOPI | SEAPID | Chulalongkorn | Erasmus MC Meeting 2026 TTCI Webinar “CAR T-cell Immunometabolism, Insights from Patients” Patient Care and Toxicities Management of CAR T-cell in Pediatrics International Collaborator IMMUNOLOGY SEMINAR: PEPTIDE CANCER VACCINE EXPERIENCE AT NCI Government Agencies and Related Announcements Efficiently targeting folate receptor alpha-positive ovarian cancer by human antibody VH domain-based chimeric antigen receptor (CAR) AP-SciBio 2027 x WIC APAC 2027 & Thai Immunology Annual Meeting Equipment Enhancing T cell cytotoxicity in multiple myeloma with bispecific αPD-L1 × αCD3 T cell engager-armed T cells and low-dose bortezomib therapy New Immune Cell Engager Combined with Chemotherapy Boosts Attack on Multiple Myeloma Registration Open: 1st International Scientific Symposium in Hematologic Malignancy (CETH, Chulalongkorn University) Khonkaen University Team University of Wisconsin School of Medicine and Public Health Antitumor activities of chimeric antigen receptor T cells targeting Mucin-1 with self-released anti-PD-1 IgG antibody A multi-center clinical research project to study the Safety and Efficacy of CD19 CAR T-cells in ALL (Acute Lymphoblastic Leukemia) by Academic Hubs Thammasat University Team Chulalongkorn University Team Enhancing T cell cytotoxicity against lung cancer with an αPD-L1 protein engager and gemcitabine combination therapy Antitumor activities of chimeric antigen receptor T cells targeting Mucin-1 with self-released anti-PD-1 IgG antibody Researchers Develop Method to Remove Specific Problematic Proteins for Improved Drug Effects Enhancing Innate and Adaptive Immunity to Combat Multiple Myeloma: Combined Use of Trispecific NK Cell Engagers (TriKEs) and Bispecific T-Cell Engagers (BiTEs) in Immunotherapy TTCI Members Receive Research Recognition Awards from Faculty of Sciences, Chiang Mai University New Dual-Targeting Protein and Chemotherapy Boost T-Cell Attack on Lung Cancer Vaccine and Therapeutic RNA Research Forum 2025 Celebrating Excellence in Immunotherapy: Dr. Piriya Luangwattananun Honored as Young Investigator Announcement: Student Progress Report 1/2025 Special Lecture: Advanced Cellular Therapeutics for Hematologic Malignancies Chula Licenses Thai PD-1 Antibody to US Biopharma นวัตกรรมเซลล์บำบัดมะเร็ง “CAR-T cell” โอกาสใหม่ของผู้ป่วยมะเร็งไทย Antibody-Drug Conjugates (ADCs): Recent Advances in the Treatment of Solid Tumors